Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparison of Pharmacokinetic-Based and Weight-Based Coagulation Factor Replacement in Hemophilia Patients Undergoing Joint Arthroplasty: A Retrospective Analysis of Perioperative Bleeding Risks and Economic Implications

  • By

  • Shuxia Zhang

  • Yi Chen

  • Haojie Qin

  • Jing Chen

  • Chunrong Chen

  • Xuemei Wu

  • Min Chen

  • Jiajun Lin

  • Fenge Yang

  • Meijuan Huang

  • July 14, 2026

Share

  • 1

    The study compared PK-guided and weight-guided coagulation factor replacement in hemophilia patients undergoing joint arthroplasty.

  • 2

    Thirty-three male patients with a median age of 39 years participated, with 75.8% having severe hemophilia.

  • 3

    The PK-guided group had significantly lower median hospitalization costs and coagulation factor consumption compared to the weight-guided group.

  • 4

    Median intraoperative blood loss and perioperative hemoglobin decrease were comparable between both replacement regimens.

  • 5

    The findings suggest that PK-guided therapy may offer clinical and economic advantages in managing hemophilia during arthroplasty.

Original Source(s)

Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes

  • by Shuxia Zhang, Yi Chen, Haojie Qin, Jing Chen, Chunrong Chen, Xuemei Wu, Min Chen, Jiajun Lin, Fenge Yang, Meijuan Huang

  • July 14, 2026

Related Content

Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

  • by

  • August 26, 2026

  • 3 min
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas